# RBC Capital

Type: Company (RY)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/rbc-capital
Canonical HTML page: https://gethealthbrief.com/entity/rbc-capital

## Recent coverage (1 stories)

### Eli Lilly’s Retatrutide Positioned as Next-Gen Obesity Powerhouse by RBC Capital
2026-03-20 05:27:44 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

RBC Capital reaffirms Eli Lilly’s Retatrutide as a critical future growth engine, despite recent mixed clinical trial data. The triple-agonist therapy is expected to redefine the weight-loss market by offering superior efficacy compared to existing dual-agonist treatments.
Full story: https://gethealthbrief.com/story/eli-lilly-retatrutide-rbc-capital-growth-driver

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.